(pankajstock123 — stock.adobe.com)Chief Operating Officer and Founder Andrew Miller also has noticed the recent slew of good news in the space. Like the other big biotechs, the growth outlook for Biogen falls flat. And that is likely the driving force behind the direction of the stock over the longer-term, with analysts forecasting only 5.7 percent revenue growth in 2018, 3 percent growth in 2019, and 3.4 percent growth in 2020. Biogen got walloped in February as part of the overall stock market sell-off, but fell even further after the company announced it would be increasing the enrollment size of two late-stage studies for its Alzheimer’s drug aducanumab. The increasing enrollment size was seen as a negative indication that perhaps Biogen didn’t see positive results coming out of the two studies. TipRanks is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who provides financial advice.

Biogen Inc stock

Last year, the neuroscience drug market was worth $32.2 billion, according to research https://dotbig.com/ firm Imarc Group. Custom Market Insights sees a smaller market, but similar growth.

SVB Securities Remains a Buy on Biogen (BIIB)

Real-time analyst ratings, insider transactions, earnings data, and more. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in https://dotbig.com/ price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report.

  • The agency decided to approve it anyway, but it has failed to live up to expectations so far.
  • This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.
  • Experts agree it’s a period of revival and vigorous activity in neuroscience.
  • For now, the technicals are pointing to a stock that can rise over the short-term, but the longer-term picture for Biogen remains a little murky.

The industry group of biotech stocks ranks eighth out of the 197 groups IBD tracks. Shares are now above their key moving averages and have a collective RS Rating of 96.


If approved, patients will have to undergo genetic testing to ensure they have that specific mutation before they can receive tofersen. Biogen can measure the amount of amyloid in a patient’s brain following treatment. There’s a growing understanding that the driving force behind dotbig one patient’s neurodegenerative disease might not be the same for another. But there are many unknowns in the neuroscience renaissance, says Wedbush analyst Laura Chico. However, experts don’t agree on whether amyloid causes Alzheimer’s or is merely a result of the disease.

Today, the field includes drugs that manipulate the immune system, targeted treatments that take advantage of genetic mutations and dotbig meds that can be described as tumor-seeking torpedoes. Free Report) closed at $254.07, marking a -0.28% move from the previous day.

Biogen Inc stock

Sign up for a Robinhood brokerage account to buy or sell Biogen stock and options commission-free. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. With slowing inflation, indications of slower rate hikes by the Fed beginning this month, and resilient employment growth, fundamentally strong stocks Biogen , APA Corporation , and Nathan’s… Live educational Forex news sessions using site features to explore today’s markets. Bloomberg Surveillance Bloomberg Surveillance with Tom Keene, Jonathan Ferro & Lisa Abramowicz live from New York, bringing insight on global markets and the top business stories of the day. The COVID-19 pandemic has made governments across the world realize the importance of healthcare and the need to develop treatments for unmet medical needs.


Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Moody’s Daily Credit Risk Score https://dotbig.com/markets/stocks/BIIB/ is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market.

Across the board, executives and analysts expect new companies to swarm to the neuroscience space, benefiting from the parade of good news. Part of what has enthused investors in Karuna is how KarXT differs from other antipsychotics BIIB stock price today on the market. The lion’s share of drugs rely on the same pathway that blocks chemicals in the brain known as dopamine and serotonin. Karuna’s drug uses a different pathway, targeting a neurotransmitter called acetylcholine.

BIIB Stock – Frequently Asked Questions

Eli Lilly & Co. said Wednesday night that its experimental Alzheimer’s treatment did a better Biogen Inc stock job at clearing amyloid plaque than Eisai and Biogen’s Aduhelm in a Phase 3 clinical trial.

Meanwhile, our latest consensus estimate is calling for revenue of $2.47 billion, down 11.1% from the https://en.wikipedia.org/wiki/Foreign_exchange_market prior-year quarter. Biogen’s relative strength index is also trading at oversold levels around 30.

Biogen currently trades at 10.8 times 2019 earning estimates of $26.19 per share, and that makes only Celgene Corp. cheaper out of the big four biotechs, including Gilead Sciences Inc. and Amgen Inc. . Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis. Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers. Biogen has 5.01% upside potential, based on the analysts’ average price target. Biogen issued an update on its FY 2022 earnings guidance on Tuesday, November, 1st. The company provided EPS guidance of $16.50-$17.15 for the period, compared to the consensus estimate of $16.49.

Biogen Inc Past Events

By doing so, Karuna hopes to offer a more robust treatment with fewer side effects. Biogen says its researchers have a long history of examining neurodegenerative diseases and now others in the industry are doing the same. It’s well established that different genetic mutations drive cancerous growths. Researchers are Biogen Inc stock price today beginning to realize the same is true for neurology. It approved Amylyx’s treatment for ALS based on a single Phase 3 study. Generally, the agency requires two placebo-controlled final-phase studies to prove a drug’s effectiveness and safety. There’s also evidence it could be as flexible for Biogen with lecanemab.